High-Throughput Screening of Novel Organometallic Compounds for Potential Anticancer Activity
DOI:
https://doi.org/10.56294/saludcyt2024.1349Keywords:
Cancer, Organometallic compounds, MCF-7, HCT-116Abstract
Introduction: Cancer still represents a substantial international challenge, and searching for new therapeutic agents is unceasing. Cancer development is assessed in this study through new organometallic compounds as potential cancer elimination agents using high-throughput screening (HTS) parameters.
Methods: This study has examined a wide variety of organometallic compounds, including MCF-7 (breast cancer) line cells, A549 (lung cancer), and HCT-116 (colon cancer).
Results: High-throughput screening identified three novel compounds, OM-101, OM-202, and OM-303, with potential anticancer activity against specific cancer cell lines. OM-101 exhibited high potency in MCF-7 breast cancer cells (IC50 = 1.2 μM) by inducing apoptosis, while OM-202 demonstrated the most potent activity in A549 lung cancer cells (IC50 = 0.8 μM) through DNA intercalation. OM-303, with an IC50 of 1.5 μM in HCT-116 colon cancer cells, was associated with reactive oxygen species (ROS) generation but requires further investigation. Validation assays confirmed these mechanisms, refining the IC50 values for OM-101 (1.1 μM), OM-202 (0.7 μM), and OM-303 (1.4 μM). These results highlight OM-101 and OM-202 as promising therapeutic candidates, with OM-303 necessitating additional studies to elucidate its potential.
Conclusion: these findings collectively underscore the potential of OM-101 and OM-202 as strong therapeutic candidates, with OM-303 requiring further exploration to clarify its efficacy and mechanism
References
1. Nabiev I, Chourpa I, Manfait M. Interactions of anticancer metallodrugs with DNA analyzed by surface-enhanced Raman spectroscopy. Biochimie. 1994;76(5):471-85. https://doi.org/10.1016/0300-9084(94)90016-7
2. Ott I, Gust R. Non-platinum metal complexes as anti-cancer drugs. Arch Pharm Res. 2007;30(3):291-9. https://doi.org/10.1007/s12272-001-1114-x
3. Farrell N. Metal complexes as drugs and chemotherapeutic agents. Chem Ind. 2002;9(11):276-9. https://doi.org/10.1016/S0367-8398(01)00204-7
4. Barry NP, Sadler PJ. Exploration of the medical periodic table: Towards new targets. Chem Commun. 2013;49(45):5106-31. https://doi.org/10.1039/c3cc00080f
5. Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: Targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev. 2016;116(5):3436-86. https://doi.org/10.1021/acs.chemrev.5b00597
6. Butler JS, Sadler PJ. Targeted delivery of platinum-based anticancer complexes. Curr Opin Chem Biol. 2013;17(2):175-88. https://doi.org/10.1016/j.cbpa.2013.01.002
7. Clarke MJ. Ruthenium metallopharmaceuticals. Coord Chem Rev. 2002;232(1-2):69-93. https://doi.org/10.1016/S0010-8545(02)00084-5
8. Bergamo A, Sava G. Ruthenium complexes can target determinants of tumor malignancy. Dalton Trans. 2007;13(12):1267-72. https://doi.org/10.1039/b616858k
9. Hasan MS, Abdulgafor AB, Hussein MA, Owain MS, Aboud QM, Al-Zobaie AJ. In-vitro and in-vivo therapeutic study the effect of Ca-EDTA against Salmonella typhimurium infection in experimental local rabbits. J Pharm Sci Res. 2018;10(7):1765-7.
10. Gibson D. Platinum complexes as DNA intercalators. Chem Rev. 2009;109(9):2829-43. https://doi.org/10.1021/cr800406f
11. Hartinger CG, Dyson PJ. Bioorganometallic chemistry: A field of the future. Chem Soc Rev. 2009;38(2):391-401. https://doi.org/10.1039/b801889k
12. Ibrahim ZY, Ali BH, Ali RK, Jarad AS, Farhan WH, Hasan MS. Avian Candidiasis: A Review. Int J Pharm Res. 2020;12(1).
13. Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and clinical trials. Dalton Trans. 2010;39(11):8113-27. https://doi.org/10.1039/c0dt00292e
14. Reedijk J. Improved understanding of platinum antitumor chemistry. Chem Commun. 2008;42(2):1760-70. https://doi.org/10.1039/b719588j
15. Ang WH, Dyson PJ. Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy. Eur J Inorg Chem. 2006;2006(20):4003-18. https://doi.org/10.1002/ejic.200600229
Published
Issue
Section
License
Copyright (c) 2024 Al Luaibi Abeer Issa Mohammad, Aula J. Naji , Haitham S. Hamadi (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
